OxThera AB

Pathalys Pharma, Inc. is nearing the clinical trial finish line with upacicalcet, which it is testing in two Phase III trials for the treatment of secondary hyperparathyroidism (SHPT) in patients wit

Valued-based agreements have become a hallmark patient-access strategy for Alnylam Pharmaceuticals Inc. ’s high priced rare disease RNA-interference therapies, and it has agreements in principle in p

Alnylam Pharmaceuticals Inc. detailed its pediatric data for lumasiran in primary hyperoxaluria type 1 (PH1) on 22 October, showing the RNA-interference therapy works roughly as well and with similar

Alnylam Pharmaceuticals Inc. ’s lumasiran already is on track to become the first approved drug therapy for the ultra-rare renal disorder primary hyperoxaluria 1 (PH1), but top-line data the biotech u